SPDR S&P Biotech ETF (XBI)
AMEX: XBI
· Real-Time Price · USD
101.64
1.44 (1.44%)
At close: Oct 01, 2025, 1:47 PM
1.44% (1D)
| Bid | 101.63 |
| Market Cap | 5.22B |
| AUM | 5.53B |
| NAV | 99.41 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 51.35M |
| Inception Date | Jan 30, 2006 |
| Ask | 101.67 |
| Volume | 6,215,438 |
| Open | 100.11 |
| Previous Close | 100.20 |
| Day's Range | 100.11 - 102.15 |
| 52-Week Range | 66.66 - 105.47 |
| Holdings | 134 |
| Expense Ratio | 0.35% |
About XBI
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select IndustryTM Index (the “Index”)Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: BiotechnologySeeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocksAllows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing
Asset Class Equity
Ticker Symbol XBI
Inception Date Jan 30, 2006
Provider State Street
Website Fund Home Page
Exchange AMEX
Top 10 Holdings 19.28% of assets
| Name | Symbol | Weight |
|---|---|---|
| Crispr Therapeutics ... | CRSP | 2.20% |
| United Therapeutics ... | UTHR | 2.03% |
| Abbvie Inc. | ABBV | 1.94% |
| Exelixis, Inc. | EXEL | 1.93% |
| Regeneron Pharmaceut... | REGN | 1.89% |
| Moderna, Inc. | MRNA | 1.87% |
| Neurocrine Bioscienc... | NBIX | 1.87% |
| Ionis Pharmaceutical... | IONS | 1.86% |
| Vertex Pharmaceutica... | VRTX | 1.85% |
| Biomarin Pharmaceuti... | BMRN | 1.84% |
Dividends Dividend Yield 0.04%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Sep 22, 2025 | $0.0267 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.0053 | Mar 26, 2025 |
| Dec 23, 2024 | $0.0027 | Dec 26, 2024 |
| Sep 23, 2024 | $0.0152 | Sep 25, 2024 |
4 months ago
-6.63%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
